{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:55:17Z","timestamp":1778266517050,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.012","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T23:05:53Z","timestamp":1477004753000},"page":"74-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Fabio","family":"Nascimbeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Dalla Salda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.012_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"Suppl 1","key":"10.1016\/j.bcmd.2016.10.012_bb0015","first-page":"S6","article-title":"Understanding the natural history of Gaucher disease","volume":"90","author":"Mistry","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0020","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0030","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s12325-014-0174-0","article-title":"Management of bone disease in Gaucher disease type 1: clinical practice","volume":"31","author":"Giuffrida","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0040","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21305","article-title":"Life expectancy in Gaucher disease type 1","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3565","article-title":"Signals from the lysosome: a control centre for cellular clearance and energy metabolism","volume":"14","author":"Settembre","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jmcb\/mjt022","article-title":"The lysosome: from waste bag to potential therapeutic target","volume":"5","author":"Appelqvist","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1083\/jcb.201607005","article-title":"The lysosome as a command-and-control center for cellular metabolism","volume":"214","author":"Lim","year":"2016","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/ncb3114","article-title":"Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB","volume":"17","author":"Medina","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0070","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ncb2718","article-title":"TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop","volume":"15","author":"Settembre","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal disorders: from storage to cellular damage","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.04.005","article-title":"Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance","volume":"11","author":"Yang","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0090","doi-asserted-by":"crossref","first-page":"E705","DOI":"10.1073\/pnas.1113036109","article-title":"Inhibitory effect of dietary lipids on chaperone-mediated autophagy","volume":"109","author":"Rodriguez-Navarro","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0095","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.cmet.2013.11.001","article-title":"Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation","volume":"18","author":"Xu","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0105","doi-asserted-by":"crossref","first-page":"G1102","DOI":"10.1152\/ajpgi.00095.2016","article-title":"Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance","volume":"310","author":"Ilan","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0110","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","article-title":"Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements","volume":"38","author":"Barton","year":"1989","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(97)00134-4","article-title":"Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease","volume":"103","author":"Hollak","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","article-title":"Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience","volume":"30","author":"Grigorescu Sido","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0125","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcmd.2010.10.008","article-title":"Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil","volume":"46","author":"Doneda","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1476-511X-9-113","article-title":"Sphingolipids: the nexus between Gaucher disease and insulin resistance","volume":"9","author":"Fuller","year":"2010","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0140","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.febslet.2015.09.018","article-title":"Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: evidence and mechanisms","volume":"589","author":"Lipina","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0145","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bcmd.2007.10.004","article-title":"Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention","volume":"40","author":"Meikle","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin. Chim. Acta; International Journal of Clinical Chemistry"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0155","first-page":"2653","article-title":"Increased basal glucose production in type 1 Gaucher's disease","volume":"80","author":"Corssmit","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.metabol.2006.10.014","article-title":"Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia","volume":"56","author":"Langeveld","year":"2007","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0165","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1210\/jc.2007-1702","article-title":"Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance","volume":"93","author":"Langeveld","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ymgme.2008.10.001","article-title":"A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight","volume":"96","author":"Ucar","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0175","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1399-0004.1984.tb00799.x","article-title":"Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease","volume":"26","author":"Ginsberg","year":"1984","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0195","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(97)09490-7","article-title":"Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia","volume":"351","author":"Pocovi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0026-0495(88)90102-3","article-title":"Abnormalities in lipoprotein metabolism in Gaucher type 1 disease","volume":"37","author":"Le","year":"1988","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0205","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(99)00188-9","article-title":"Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease","volume":"353","author":"Cenarro","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10545-012-9529-3","article-title":"Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study","volume":"36","author":"Zimmermann","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.atherosclerosis.2009.10.015","article-title":"Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy","volume":"209","author":"Puzo","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2141.2010.08167.x","article-title":"Diagnosis of severe type 1 Gaucher's disease before irreversible damage occurs: is HDL cholesterol the answer?","volume":"150","author":"Cohen","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0225","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10545-010-9271-7","article-title":"Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity","volume":"34","author":"Stein","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.clnu.2014.08.010","article-title":"Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy","volume":"34","author":"Doneda","year":"2015","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","article-title":"Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease","volume":"204","author":"de Fost","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0245","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0016-5085(81)90202-X","article-title":"Liver abnormalities in patients with Gaucher's disease","volume":"80","author":"James","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/qjmed\/93.4.237","article-title":"Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features","volume":"93","author":"Lachmann","year":"2000","journal-title":"QJM: Monthly Journal of the Association of Physicians"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057507","article-title":"Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage","volume":"8","author":"Bohte","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2016.10.012_bb0260","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-2005-871201","article-title":"Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature","volume":"25","author":"Xu","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0265","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"de Fost","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0270","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","article-title":"The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients","volume":"84","author":"Taddei","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0275","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12335","article-title":"Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature","volume":"161","author":"Arends","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0280","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bcmd.2016.06.009","article-title":"Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease","volume":"60","author":"Regenboog","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.012_bb0285","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit. Rev. Oncog."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:48Z","timestamp":1761050028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":57,"alternative-id":["S1079979616302285"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.012","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}